Agreement - January 1, 2016
Camurus in agreement with Rhythm
The two companies have entered a license agreement for the use of Camurus’ drug delivery technology, FluidCrystal, to formulate setmelanotide (RM-493), Rhythm’s novel melanocortin-4 receptor (MC4R) agonist. Under the terms of the agreement, Camurus has granted Rhythm a worldwide license to the FluidCrystal technology to formulate setmelanotide and to develop, manufacture, and commercialize this new […]
Agreement - December 23, 2015
Karolinska Development, Karolinska Institutet Holding signs agreement
Karolinska Development and Karolinska Institutet Holding AB, a company wholly owned by Karolinska Institutet (KI) have signed a new non-exclusive deal flow agreement. This agreement is a key element of a new strategy designed to improve the translation of medical innovations originating from KI into commercial enterprises that can generate value for all stakeholders. As part […]
Agreement - December 23, 2015
Sectra signa contract with Swedish County Council
Sectra has signed a multi-year contract with Norrbottens Läns Landsting (NLL), a Swedish County Council. NLL has purchased Sectra’s IT solution for efficient handling of radiology images and patient information (PACS and RIS) as a cloud service hosted within the healthcare organization. Under the contract, Sectra will assume overall responsibility for technology, administration and maintenance […]
Agreement - December 22, 2015
Recipharm signs agreement with Alcon
Recipharm signs manufacturing agreement with Alcon and acquires facility in France, adding new niche capabilities. Recipharm AB has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and today signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology. As part of this collaboration, Recipharm will also […]
Agreement - December 17, 2015
Recipharm and LIDDS signs contract
Recipharm and LIDDS have signed an exclusive collaboration agreement regarding scale-up of the production process and commercial manufacture of Liproca Depot, LIDDS patented targeted treatment for prostate cancer. The agreement will be an important component for the upcoming Phase IIb study which is planned to start in 2016. In connection with the agreement, Recipharm invests […]
Agreement - November 27, 2015
Pelago Bioscience, AstraZeneca enter agreement
Pelago Bioscience AB and AstraZeneca have entered into a 2-year strategic research collaboration and license agreement. The companies will collaborate on specified joint projects and AstraZeneca will also be granted a license to use and apply the Cellular Thermal Shift Assay (CETSA®) for determination and quantification of drug–target interactions in other AstraZeneca discovery projects. During the […]
